Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2021 Jun 23

PMID 34161567

Citations 31

Authors

Khalid Shrwani

Ravi Sharma

Madhan Krishnan

Terry Jones

Martin Mayora-Neto

Diego Cantoni

Nigel J Temperton

Susan L Dobson

Krishanthi Subramaniam

Paul S McNamara

Nigel A Cunliffe

Lance Turtle

Qibo Zhang

Affiliations

Soon will be listed here.

Abstract

Background: A notable feature of coronavirus disease 2019 (COVID-19) is that children are less susceptible to severe disease. Children are known to experience more infections with endemic human coronaviruses (HCoVs) compared to adults. Little is known whether HCoV infections lead to cross-reactive anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies.

Methods: We investigated the presence of cross-reactive anti-SARS-CoV-2 IgG antibodies to spike 1 (S1), S1-receptor-binding domain (S1-RBD), and nucleocapsid protein (NP) by enzyme-linked immunosorbent assays, and neutralizing activity by a SARS-CoV-2 pseudotyped virus neutralization assay, in prepandemic sera collected from children (n = 50) and adults (n = 45), and compared with serum samples from convalescent COVID-19 patients (n = 16).

Results: A significant proportion of children (up to 40%) had detectable cross-reactive antibodies to SARS-CoV-2 S1, S1-RBD, and NP antigens, and the anti-S1 and anti-S1-RBD antibody levels correlated with anti-HCoV-HKU1 and anti-HCoV-OC43 S1 antibody titers in prepandemic samples (P < .001). There were marked increases of anti-HCoV-HKU1 and - OC43 S1 (but not anti-NL63 and -229E S1-RBD) antibody titers in serum samples from convalescent COVID-19 patients (P < .001), indicating an activation of cross-reactive immunological memory to β-coronavirus spike.

Conclusions: We demonstrated cross-reactive anti-SARS-CoV-2 antibodies in prepandemic serum samples from children and young adults. Promoting this cross-reactive immunity and memory response derived from common HCoV may be an effective strategy against SARS-COV-2 and future novel coronaviruses.

Citing Articles

Longitudinal Surveillance of COVID-19 Antibodies in Pediatric Healthcare Workers.

Hatabah D, Gupta S, Mantus G, Sullivan P, Heilman S, Camacho-Gonzalez A Vaccines (Basel). 2025; 13(2).

PMID: 40006710 PMC: 11861628. DOI: 10.3390/vaccines13020163.

Evidence of rapid rise in population immunity from SARS-CoV-2 subclinical infections through pre-vaccination serial serosurveys in Pakistan.

Iqbal J, Hasan Z, Habib M, Malik A, Muhammad S, Begum K J Glob Health. 2025; 15:04078.

PMID: 39977666 PMC: 11842006. DOI: 10.7189/jogh.15.04078.

Pre-existing IgG antibodies to HCoVs NL63 and OC43 Spike increased during the pandemic and after COVID-19 vaccination.

Hasan Z, Masood K, Veldhoen M, Qaiser S, Alenquer M, Akhtar M Heliyon. 2025; 11(3):e42171.

PMID: 39916832 PMC: 11795784. DOI: 10.1016/j.heliyon.2025.e42171.

T cell hybrid immunity against SARS-CoV-2 in children: a longitudinal study.

Qui M, Hariharaputran S, Hang S, Zhang J, Tan C, Chong C EBioMedicine. 2024; 105:105203.

PMID: 38896919 PMC: 11237860. DOI: 10.1016/j.ebiom.2024.105203.

Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence.

Bean D, Monroe J, Liang Y, Borberg E, Senussi Y, Swank Z Sci Transl Med. 2024; 16(751):eado7588.

PMID: 38865483 PMC: 11565543. DOI: 10.1126/scitranslmed.ado7588.

References

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

Gaunt E, Hardie A, Claas E, Simmonds P, Templeton K . Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol. 2010; 48(8):2940-7. PMC: 2916580. DOI: 10.1128/JCM.00636-10. View

Sampson A, Heeney J, Cantoni D, Ferrari M, Sans M, George C . Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses. Viruses. 2021; 13(8). PMC: 8402765. DOI: 10.3390/v13081579. View

Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z . Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020; 145(6). DOI: 10.1542/peds.2020-0702. View

Lv H, Wu N, Tsang O, Yuan M, Perera R, Leung W . Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep. 2020; 31(9):107725. PMC: 7231734. DOI: 10.1016/j.celrep.2020.107725. View

Friedman N, Alter H, Hindiyeh M, Mendelson E, Avni Y, Mandelboim M . Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1. Viruses. 2018; 10(10). PMC: 6213580. DOI: 10.3390/v10100515. View

McMahan K, Yu J, Mercado N, Loos C, Tostanoski L, Chandrashekar A . Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2020; 590(7847):630-634. PMC: 7906955. DOI: 10.1038/s41586-020-03041-6. View

Paules C, Marston H, Fauci A . Coronavirus Infections-More Than Just the Common Cold. JAMA. 2020; 323(8):707-708. DOI: 10.1001/jama.2020.0757. View

10.

Bacher P, Rosati E, Esser D, Martini G, Saggau C, Schiminsky E . Low-Avidity CD4 T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. Immunity. 2020; 53(6):1258-1271.e5. PMC: 7689350. DOI: 10.1016/j.immuni.2020.11.016. View

11.

Che X, Qiu L, Liao Z, Wang Y, Wen K, Pan Y . Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43. J Infect Dis. 2005; 191(12):2033-7. PMC: 7109809. DOI: 10.1086/430355. View

12.

Anderson E, Goodwin E, Verma A, Arevalo C, Bolton M, Weirick M . Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell. 2021; 184(7):1858-1864.e10. PMC: 7871851. DOI: 10.1016/j.cell.2021.02.010. View

13.

Hashimoto G, Wright P, Karzon D . Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis. 1983; 148(5):785-94. DOI: 10.1093/infdis/148.5.785. View

14.

Huang A, Garcia-Carreras B, Hitchings M, Yang B, Katzelnick L, Rattigan S . A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020; 11(1):4704. PMC: 7499300. DOI: 10.1038/s41467-020-18450-4. View

15.

Song G, He W, Callaghan S, Anzanello F, Huang D, Ricketts J . Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nat Commun. 2021; 12(1):2938. PMC: 8134462. DOI: 10.1038/s41467-021-23074-3. View

16.

Mahallawi W, Kasbekar A, McCormick M, Hoschler K, Temperton N, Leong S . Infection with 2009 H1N1 influenza virus primes for immunological memory in human nose-associated lymphoid tissue, offering cross-reactive immunity to H1N1 and avian H5N1 viruses. J Virol. 2013; 87(10):5331-9. PMC: 3648155. DOI: 10.1128/JVI.03547-12. View

17.

Ng K, Faulkner N, Cornish G, Rosa A, Harvey R, Hussain S . Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020; 370(6522):1339-1343. PMC: 7857411. DOI: 10.1126/science.abe1107. View

18.

Sagar M, Reifler K, Rossi M, Miller N, Sinha P, White L . Recent endemic coronavirus infection is associated with less-severe COVID-19. J Clin Invest. 2020; 131(1). PMC: 7773342. DOI: 10.1172/JCI143380. View

19.

Bunyavanich S, Do A, Vicencio A . Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. JAMA. 2020; 323(23):2427-2429. PMC: 7240631. DOI: 10.1001/jama.2020.8707. View

20.

Grifoni A, Weiskopf D, Ramirez S, Mateus J, Dan J, Rydyznski Moderbacher C . Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181(7):1489-1501.e15. PMC: 7237901. DOI: 10.1016/j.cell.2020.05.015. View